{"id":251778,"date":"2021-03-05T00:00:00","date_gmt":"2021-03-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidim0124-biopharma-pemphigus-vulgaris-epidemiology-mature-markets\/"},"modified":"2026-05-03T23:33:35","modified_gmt":"2026-05-03T23:33:35","slug":"epidim0124-biopharma-pemphigus-vulgaris-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0124-biopharma-pemphigus-vulgaris-epidemiology-mature-markets\/","title":{"rendered":"Pemphigus Vulgaris &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p><abbr title=\"Decision Resources Group\">DRG<\/abbr> Epidemiology&#8217;s coverage of pemphigus vulgaris comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report both the diagnosed incidence and prevalence of <abbr title=\"pemphigus vulgaris\">PV<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p><abbr title=\"Decision Resources Group\">DRG<\/abbr> Epidemiology&#8217;s PV\u00a0forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How many people in each country across the major mature pharmaceutical markets have been formally diagnosed with <abbr title=\"pemphigus vulgaris\">PV<\/abbr>?<\/li>\n<li>How does the severity of <abbr title=\"hidradenitis suppurativa\">HS<\/abbr> differ between newly diagnosed and existing prevalent <abbr title=\"pemphigus vulgaris\">PV<\/abbr> cases?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"pemphigus vulgaris\">PV<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the <abbr title=\"Decision Resources Group\">DRG<\/abbr> Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, <abbr title=\"Decision Resources Group\">DRG<\/abbr> Epidemiology forecasts five\u00a0<abbr title=\"hidradenitis suppurativa\">HS<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases.<\/li>\n<li>Diagnosed prevalent cases.<\/li>\n<li>Diagnosed incident cases by severity.<\/li>\n<\/ul>\n<p>Note: coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251778","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251778\/revisions"}],"predecessor-version":[{"id":284232,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251778\/revisions\/284232"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}